Literature DB >> 9613753

Extensor truncal dystonia: successful treatment with botulinum toxin injections.

C L Comella1, K M Shannon, J Jaglin.   

Abstract

Patients with truncal extension dystonia, manifested by involuntary back arching, often associated with pain and severe motor disability, have not consistently responded to pharmacologic agents. We evaluated 4 women and 1 man (mean age, 41.8 years; dystonia duration, 9.8 years) with severe idiopathic (2 patients) or tardive (3 patients) truncal and cervical dystonia. Using electromyographic guidance, we injected botulinum toxin into the paravertebral muscles of the lumbar region in four to six sites using 25-50 U per site. We reevaluated patients 2-4 weeks after injection. The mean dose of botulinum toxin into back muscles was 210 U (range, 150-300 U). By blinded videotape evaluation, objective improvement was found in three patients with a mean truncal dystonia score improving by 37%. Patient evaluation showed improvement in movement ranging from 20-80% (mean, 46%) after botulinum toxin. In all patients with pain as a result of dystonia, there was substantial improvement. None of the patients worsened and no adverse effects occurred. Botulinum toxin injections offer a potent new treatment for truncal dystonia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613753     DOI: 10.1002/mds.870130330

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

1.  Mechanism of Botulinum Toxin in the Relief of Chronic Pain.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

Review 2.  [Use of botulinum toxin the the treatment of muscle pain].

Authors:  R Benecke; D Dressler; E Kunesch; T Probst
Journal:  Schmerz       Date:  2003-12       Impact factor: 1.107

3.  Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms.

Authors:  Alessandro Di Matteo; Alfonso Fasano; Giovanna Squintani; Lucia Ricciardi; Tommaso Bovi; Antonio Fiaschi; Paolo Barone; Michele Tinazzi
Journal:  J Neurol       Date:  2010-11-16       Impact factor: 4.849

4.  Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.

Authors:  Andrea Santamato; Maurizio Ranieri; Francesco Panza; Stefano Zoccolella; Vincenza Frisardi; Vincenzo Solfrizzi; Maria Teresa Amoruso; Loredana Amoruso; Pietro Fiore
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

5.  Current and future medical treatment in primary dystonia.

Authors:  Cathérine C S Delnooz; Bart P C van de Warrenburg
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

Review 6.  The focal dystonias: current views and challenges for future research.

Authors:  H A Jinnah; Alfredo Berardelli; Cynthia Comella; Giovanni Defazio; Mahlon R Delong; Stewart Factor; Wendy R Galpern; Mark Hallett; Christy L Ludlow; Joel S Perlmutter; Ami R Rosen
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

7.  Pisa syndrome in Parkinson's disease: an electrophysiological and imaging study.

Authors:  Michele Tinazzi; Ina Juergenson; Giovanna Squintani; Gaetano Vattemi; Stefania Montemezzi; Daniela Censi; Paolo Barone; Tommaso Bovi; Alfonso Fasano
Journal:  J Neurol       Date:  2013-05-22       Impact factor: 4.849

8.  Tardive Dystonia.

Authors:  Frank Skidmore; Stephen G Reich
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

9.  The psoas muscle as cause of low back pain in infantile cerebral palsy.

Authors:  G Marrè-Brunenghi; R Camoriano; M Valle; S Boero
Journal:  J Orthop Traumatol       Date:  2008-03-13

10.  Globus Pallidus Internus Deep Brain Stimulation for Dystonic Opisthotonus in Adult-Onset Dystonia: A Personalized Approach.

Authors:  Kantharuby Tambirajoo; Luciano Furlanetti; Michael Samuel; Keyoumars Ashkan
Journal:  Front Hum Neurosci       Date:  2021-06-10       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.